Shoreline Biosciences
PrivateLast Round
Series B
Nov 2, 2021
Est. Valuation
$68.3M
Total Funding Raised
$186M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Shoreline Biosciences operates in Healthcare & Life Sciences and is based in San Diego, California. Its latest recorded funding round was a Series B round in November 2021.
Shoreline Biosciences is a biotechnology company that develops innovative immunotherapies utilizing engineered Induced Pluripotent Stem Cells (iPSC)-derived NK cells and macrophages for oncology and disease modification.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Shoreline Biosciences Comparables
Compare Shoreline Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| CytoImmune Therapeutics | 85% | |
| HebeCell | 85% | |
| CellOrigin Biotech | 84% |
For institutional investors. Book with your work email.
Shoreline Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Nov 2, 2021 | ||||
| Series A | Apr 7, 2021 | ||||
| Seed | Jul 1, 2020 |
For institutional investors. Book with your work email.
Shoreline Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Stork Capital | Series B, Series A, Seed |
| Janus Henderson Group | Series B, Series A |
| Wedbush Healthcare Partners | Series B, Series A |
| Boxer Capital | Series B, Series A |
| Ally Bridge Group | Series B |
| Heartland Healthcare Capital | Series B |
| Cormorant Asset Management | Series B, Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors grew 32% MoM, from 1.3K to 1.7K.
- Nov 2, 2021
$140M round led by Ally Bridge Group
For institutional investors. Book with your work email.
Shoreline Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Shoreline Biosciences's valuation, stock price, and market status.
Is Shoreline Biosciences a public or private company?
Shoreline Biosciences is a private company.
What is the current stock price of Shoreline Biosciences?
Shoreline Biosciences is a private company, so its shares have no public market price. Caplight tracks Shoreline Biosciences's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Shoreline Biosciences worth (valuation)?
Shoreline Biosciences's valuation is estimated at $68.3M based on funding round data.
Can I buy Shoreline Biosciences stock?
Shoreline Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Shoreline Biosciences's last funding round?
Shoreline Biosciences's most recent funding round was Series B on November 2, 2021.
Who are the main investors in Shoreline Biosciences?
Key investors in Shoreline Biosciences include Stork Capital, Boxer Capital, Ally Bridge Group.
Will Shoreline Biosciences IPO soon?
No public IPO plans have been announced for Shoreline Biosciences.
How can I track Shoreline Biosciences secondary market activity?
Caplight tracks bids, offers, and trades in Shoreline Biosciences's shares on secondary markets.